(d) Election of Directors

On May 19, 2017, the Board of Directors of Medizone
International, Inc. (Company) appointed Stephen F. Meyer, as a
member of the Board of Directors. From December 2010 until the
companys merger with Hill-Rom, Inc. in October 2015, Mr. Meyer
was an executive of Welch Allyn, Inc., a producer of diagnostic
devices, software and services for healthcare professionals,
headquartered in Skaneateles Falls, New York. He joined Welch
Allyn in 1981 as a sales representative in Detroit, Michigan. Mr.
Meyer held a series of executive and senior leadership roles in a
variety of areas from international sales and marketing to
product development, operations, and general management. As
President and CEO, Mr. Meyer navigated Welch Allyn during a time
of substantial industry change, developing and executing a new
strategy, restructuring the business, engaging more deeply with
customers, and becoming more acquisitive. Mr. Meyer is an
executive advisor to Beecken Petty OKeefe Company, a private
equity management firm that focuses on the healthcare industry,
is a member of the board of directors of Paragon Medical, Inc.
and SRC Ventures, Inc., and is an advisor to Medical Distribution
Solutions, Inc. He also is a founder and the managing director of
River Marsh Capital, LLC, a firm investing primarily in
healthcare developments which enhance and improve health, and
providing corporate advisory services to companies, private
equity, and venture firms. He is a past board member of TIDI
Medical Products LLC, a past board member and chair of MedTech
(Central New Yorks Medical Technology Association), a past board
member and president of the Health Industry Manufacturers
Marketing Council, a past board member of AdvaMed and Medical
Device Manufacturers Association, and past board member of AAFPs
Foundation. Mr. Meyer received a Bachelor of Science in Biology
from Alma College and earned a Masters of Business Administration
from the William E. Simon Graduate School of Business at the
University of Rochester, New York. The Board of Directors of
Medizone believes that Mr. Meyers qualifications to serve on the
Board of Directors include his demonstrated leadership skills and
his extensive knowledge of and experience in the healthcare
industry.

Mr. Meyer will serve as a member of the audit committee and the
compensation committee of the Board of Directors. Mr. Meyer was
not appointed to his position to any arrangement or understanding
with any other person, and he has no reportable transactions
under Item 404(a) of Regulation S-K. The Board of Directors has
determined that Mr. Meyer meets the qualifications of an audit
committee member, as defined by the applicable regulations
promulgated by the Securities and Exchange Commission
(Commission) under the Securities Exchange Act of 1934, as
amended and that he qualifies as independent as the term is used
in Item 407 of Regulation S-K as promulgated by the Commission
and as that term is defined under NASDAQ Rule 4200(a)(15).

The Board of Directors granted Mr. Meyer an option award under
the Companys 2016 Equity Incentive Award Plan for the purchase of
500,000 shares of common stock at $0.06 per share. The option
vests one-half (250,000 shares) on the date of grant and one-half
(250,000 shares) when the Board of Directors determines the
successful placement of the Companys AsepticSure hospital
disinfection system in the United States market has commenced.
The option expires in May 2027.

The press release is furnished herewith as Exhibit 99.1 and is
incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On May 22, 2017, the Company issued a press release announcing
the appointment of Mr. Meyer as a member of the Board of
Directors, a copy of which is attached as Exhibit 99.1 to this
Current Report on Form 8-K. The information in this Item 7.01 and
Exhibit 99.1 attached hereto shall not be deemed filed for
purposes of Section 18 of the Exchange Act, or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits